Clinical Trial Update: Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age. [Phase 3]

View source ↗

Summary

Phase 3 immunogenicity and safety update for GSK's HPV vaccine (GSK580299) in healthy females aged 10-25; trial completed with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• GSK580299

Snippet

Sponsor: GlaxoSmithKline | Conditions: Human Papillomavirus (HPV) Infection | Phase 3 | Status: COMPLETED | Results posted: 2011-03-24